Enhancement of Th1 type cytokine production and primary T cell activation by PBI-1393

Morgan, 1976, Selective in vitro growth of T lymphocytes from normal human bone marrow, Science, 193, 1007, 10.1126/science.181845 Smith, 1988, Interleukin-2: inception, impact, and implications, Science, 240, 1169, 10.1126/science.3131876 Ibayashi, 1987, In vivo and in vitro activation of NK cytotoxicity with IL-2, Prog. Clin. Biol. Res., 244, 275 Zhu, 1993, Activation of human monocyte/macrophage cytotoxicity by IL-2/IFN gamma is linked to increased expression of an antitumor receptor with specificity for acetylated mannose, Immunol. Lett., 38, 111, 10.1016/0165-2478(93)90175-2 Ferrante, 1992, Activation of neutrophils by interleukins-1 and -2 and tumor necrosis factors, Immunol. Ser., 57, 417 Dillman, 1994, The clinical experience with interleukin-2 in cancer therapy, Cancer Biother., 9, 183, 10.1089/cbr.1994.9.183 McDermott, 2004, Application of IL-2 and other cytokines in renal cancer, Expert Opin. Biol. Ther., 4, 455, 10.1517/14712598.4.4.455 Cooney, 2005, Promising systemic therapy for renal cell carcinoma, Curr. Treatm. Opt. Oncol., 6, 357, 10.1007/s11864-005-0039-5 Young, 1990, Interferon-gamma: producer cells, activation stimuli, and molecular genetic regulation, Pharmacol. Ther., 45, 137, 10.1016/0163-7258(90)90012-Q Bradley, 1996, A direct role for IFN-gamma in regulation of Th1 cell development, J. Immunol., 157, 1350, 10.4049/jimmunol.157.4.1350 Wenner, 1996, Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development, J. Immunol., 156, 1442, 10.4049/jimmunol.156.4.1442 Murray, 1994, Interferon-gamma and host antimicrobial defense: current and future clinical applications, Am. J. Med., 97, 459, 10.1016/0002-9343(94)90326-3 Aoki, 2004, Use of cytokines in infection, Expert Opin. Emerg. Drugs, 9, 223, 10.1517/14728214.9.2.223 Gupta, 1990, Regulation of cellular gene expression by interferon-gamma: involvement of multiple pathways, Int. J. Cell Cloning, 8, 92, 10.1002/stem.5530080709 Steimle, 1994, Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA, Science, 265, 106, 10.1126/science.8016643 Mouy, 1991, Interferon gamma for chronic granulomatous disease, N. Engl. J. Med., 325, 1516, 10.1056/NEJM199111213252115 Mattson, 1991, Recombinant interferon gamma treatment in non-small cell lung cancer. Antitumour effect and cardiotoxicity, Acta Oncol., 30, 607, 10.3109/02841869109092427 Loftis, 2004, The phenomenology and treatment of interferon-induced depression, J. Affect. Disord., 82, 175, 10.1016/j.jad.2004.04.002 Hadden, 1993, Immunostimulants, Immunol. Today, 14, 275, 10.1016/0167-5699(93)90045-M Khoo, 1984, Levamisole as adjuvant to chemotherapy of ovarian cancer. Results of a randomized trial and 4-year follow-up, Cancer, 54, 986, 10.1002/1097-0142(19840915)54:6<986::AID-CNCR2820540607>3.0.CO;2-G Arya, 1996, Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia, Br. J. Haematol., 93, 817, 10.1046/j.1365-2141.1996.d01-1744.x Sosa, 1992, Potentiation of immune responses in mice by a new inosine derivative-methyl inosine monophosphate (MIMP), Int. J. Immunopharmacol., 14, 1259, 10.1016/0192-0561(92)90062-P Zacharie, 1997, Synthesis and activity of 6-substituted purine linker amino acid immunostimulants, J. Med. Chem., 40, 2883, 10.1021/jm960844m Kadhim, 2000, Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide, Int. J. Immunopharmacol., 22, 659, 10.1016/S0192-0561(00)00028-X Puntschart, 1998, Expression of fos and jun genes in human skeletal muscle after exercise, Am. J. Physiol.: Cell Physiol., 274, 129, 10.1152/ajpcell.1998.274.1.C129 Patra, 2004, Active protein kinase B regulates TCR responsiveness by modulating cytoplasmic-nuclear localization of NFAT and NF-kappa B proteins, J. Immunol., 172, 4812, 10.4049/jimmunol.172.8.4812 Gaffen, 2004, Overview of interleukin-2 function, production and clinical applications, Cytokine, 28, 109, 10.1016/j.cyto.2004.06.010 Gu, 1994, Induction by concanavalin A of specific mRNAs and cytolytic function in a CD8-positive T cell hybridoma, J. Immunol., 153, 4408, 10.4049/jimmunol.153.10.4408 Jain, 1992, Analysis of the AP-1 sites in the IL-2 promoter, J. Immunol., 148, 1240, 10.4049/jimmunol.148.4.1240 Smith, 1980, T-cell growth factor, Immunol. Rev., 51, 337, 10.1111/j.1600-065X.1980.tb00327.x Bonjardim, 2005, Interferons (IFNs) are key cytokines in both innate and adaptive antiviral immune responses- and viruses counteract IFN action, Microbes Infect., 7, 569, 10.1016/j.micinf.2005.02.001 Weiss, 1984, The role of T3 in the activation of human T cells, J. Clin. Immunol., 4, 165, 10.1007/BF00914963 Weiss, 1984, The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level, J. Immunol., 133, 123, 10.4049/jimmunol.133.1.123 Hardy, 1985, Regulation of expression of the human interferon gamma gene, Proc. Natl. Acad. Sci. U. S. A., 82, 8173, 10.1073/pnas.82.23.8173 Hodge, 2002, Regulation of nuclear gamma interferon gene expression by interleukin 12 (IL-12) and IL-2 represents a novel form of posttranscriptional control, Mol. Cell. Biol., 22, 1742, 10.1128/MCB.22.6.1742-1753.2002 Khatri, 1998, Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies, J. Clin. Invest., 101, 1373, 10.1172/JCI2038 Gibellini, 1997, Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein, Blood, 89, 1654, 10.1182/blood.V89.5.1654 Gibellini, 2001, Extracellular Tat activates c-fos promoter in low serum-starved CD4+ T cells, Br. J. Haematol., 112, 663, 10.1046/j.1365-2141.2001.02576.x Wolberg, 1975, Adenosine inhibition of lymphocyte-mediated cytolysis: possible role of cyclic adenosine monophosphate, Science, 187, 957, 10.1126/science.167434 Antonysamy, 1995, Adenosine acts as an endogenous modulator of IL-2-dependent proliferation of cytotoxic T lymphocytes, J. Immunol., 155, 2813, 10.4049/jimmunol.155.6.2813 Huang, 1997, Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion, Blood, 90, 1600, 10.1182/blood.V90.4.1600 Mirabet, 1999, Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation, J. Cell. Sci., 112, 491, 10.1242/jcs.112.4.491 Erdmann, 2005, Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo, Blood, 105, 4707, 10.1182/blood-2004-04-1407 Kammer, 1988, The adenylate cyclase–cAMP–protein kinase A pathway and regulation of the immune response, Immunol. Today, 9, 222, 10.1016/0167-5699(88)91220-0 Li, 1999, CD3- and CD28-dependent induction of PDE7 required for T cell activation, Science, 283, 848, 10.1126/science.283.5403.848 Abrahamsen, 2004, TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling, J. Immunol., 173, 4847, 10.4049/jimmunol.173.8.4847 Vang, 2001, Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor, J. Exp. Med., 193, 497, 10.1084/jem.193.4.497 Fraiser, 1991, Cyclophosphamide toxicity. Characterising and avoiding the problem, Drugs, 42, 781, 10.2165/00003495-199142050-00005